Abstract
Use of Bevacizumab, an anti-VEGF monoclonal antibody with Irinotecan has shown promise in the treatment of recurrent high grade gliomas. The purpose of this study was 1. To test the feasibility of using Bevacizumab with radiation therapy in the primary management of recurrent and unresectable high grade gliomas and 2. To correlate the blood volume and vascular permeability changes with tumor volume measurements to assess the response.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
